CANB Stock Overview
Engages in the production and sale of recreational cannabis and cannabis extracts in Canada.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
CanadaBis Capital Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.06 |
52 Week High | CA$0.35 |
52 Week Low | CA$0.055 |
Beta | 0.20 |
11 Month Change | 0% |
3 Month Change | -33.33% |
1 Year Change | -78.95% |
33 Year Change | -50.00% |
5 Year Change | -81.82% |
Change since IPO | -88.24% |
Recent News & Updates
We Think CanadaBis Capital (CVE:CANB) Is Taking Some Risk With Its Debt
Aug 19Why Investors Shouldn't Be Surprised By CanadaBis Capital Inc.'s (CVE:CANB) 29% Share Price Plunge
Jul 14CanadaBis Capital (CVE:CANB) Has A Pretty Healthy Balance Sheet
May 09Recent updates
We Think CanadaBis Capital (CVE:CANB) Is Taking Some Risk With Its Debt
Aug 19Why Investors Shouldn't Be Surprised By CanadaBis Capital Inc.'s (CVE:CANB) 29% Share Price Plunge
Jul 14CanadaBis Capital (CVE:CANB) Has A Pretty Healthy Balance Sheet
May 09Earnings Working Against CanadaBis Capital Inc.'s (CVE:CANB) Share Price Following 48% Dive
Apr 02If EPS Growth Is Important To You, CanadaBis Capital (CVE:CANB) Presents An Opportunity
Feb 12Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Dec 01CanadaBis Capital (CVE:CANB) Seems To Use Debt Quite Sensibly
Jul 17CanadaBis Capital Inc.'s (CVE:CANB) Shares Climb 70% But Its Business Is Yet to Catch Up
Apr 17Auditors Have Doubts About CanadaBis Capital (CVE:CANB)
Dec 01Is CanadaBis Capital (CVE:CANB) A Risky Investment?
Aug 13Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Apr 30Is CanadaBis Capital (CVE:CANB) Using Debt Sensibly?
Jan 13Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?
Apr 07Have Insiders Been Selling CanadaBis Capital Inc. (CVE:CANB) Shares This Year?
Feb 14Here's Why CanadaBis Capital (CVE:CANB) Can Afford Some Debt
Dec 23Shareholder Returns
CANB | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | 0% | -4.7% | -0.004% |
1Y | -78.9% | 37.6% | 14.9% |
Return vs Industry: CANB underperformed the Canadian Pharmaceuticals industry which returned 38.8% over the past year.
Return vs Market: CANB underperformed the Canadian Market which returned 14.7% over the past year.
Price Volatility
CANB volatility | |
---|---|
CANB Average Weekly Movement | 13.2% |
Pharmaceuticals Industry Average Movement | 10.3% |
Market Average Movement | 8.1% |
10% most volatile stocks in CA Market | 16.7% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: CANB's share price has been volatile over the past 3 months.
Volatility Over Time: CANB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Travis McIntyre | www.canadabis.com |
CanadaBis Capital Inc. engages in the production and sale of recreational cannabis and cannabis extracts in Canada. It operates through three segments: Cultivation and Wholesale, Retail, and Extract. The Cultivation and Wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards.
CanadaBis Capital Inc. Fundamentals Summary
CANB fundamental statistics | |
---|---|
Market cap | CA$8.30m |
Earnings (TTM) | CA$2.18m |
Revenue (TTM) | CA$18.83m |
3.8x
P/E Ratio0.4x
P/S RatioIs CANB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CANB income statement (TTM) | |
---|---|
Revenue | CA$18.83m |
Cost of Revenue | CA$8.49m |
Gross Profit | CA$10.34m |
Other Expenses | CA$8.16m |
Earnings | CA$2.18m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.016 |
Gross Margin | 54.90% |
Net Profit Margin | 11.56% |
Debt/Equity Ratio | 73.9% |
How did CANB perform over the long term?
See historical performance and comparison